Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARI0002h for initial treatment of newly diagnosed primary plasma cell leukemia
2024-515053-21-00Phase 2Authorised
- Sponsor
- IDIBAPS
- Start
- Mar 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARI0002h in plasma cell leukaemia (PCL), sponsored by IDIBAPS. Primary endpoints: Overall response rate during first 3 months and Cytokine release syndrome and/or neurological toxicity rate. Planned start Mar 2025; status: authorised.
02
Drugs
ARI0002h
03
Conditions
plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on 2024-515053-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515053-21-00.